Alloy Therapeutics Acquires deepCDR Biologics

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.

Genmab Acquires ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab A/S will acquire clinical-stage biotech ProfoundBio, Inc. in an all-cash transaction valued at USD 1.8 billion to obtain worldwide rights to ProfoundBio's pipeline of antibody-drug conjugates (ADCs), including rinatabart sesutecan (Rina-S). The deal is intended to broaden and strengthen Genmab's oncology and ADC capabilities and is expected to close in the first half of 2024, subject to customary conditions.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

BioNTech SE Acquires InstaDeep Ltd.

January 10, 2023

AI & Machine Learning

BioNTech SE has agreed to acquire the remaining shares of InstaDeep Ltd. for approximately £362 million in cash and BioNTech shares, with up to ~£200 million of additional performance-based milestone payments. The acquisition brings roughly 240 AI, ML and software professionals into BioNTech to accelerate AI-driven drug discovery, embed InstaDeep’s DeepChain platform in BioNTech’s discovery pipeline, and expand BioNTech’s global AI capabilities.

Alloy Therapeutics Acquires Spannerwerks

October 23, 2025

Healthcare Services

Alloy Therapeutics has acquired Seattle-based Spannerwerks, a drug development consulting firm, which will operate as a wholly owned subsidiary and continue serving clients under the Spannerwerks name. The deal expands Alloy's capabilities beyond discovery into preclinical and clinical development, with Spannerwerks CEO Dara Lockert joining Alloy's leadership team.